Why Biotech's AI Revolution Is Finally Moving Beyond the Lab and Into the Clinic

For years, artificial intelligence in biotech has promised faster drug discovery. Now, the industry is confronting a harder truth: finding drug candidates was never the real problem. Getting them through clinical trials is.

At a recent industry showcase, nine biotech companies demonstrated a fundamental shift in how AI is being deployed across the sector. Rather than simply accelerating early-stage target identification, these platforms are focused on the industry's most expensive bottleneck—the 90-95% clinical failure rate that turns promising laboratory compounds into failed therapies. The new approach: use AI to predict which drugs will actually work in patients before committing hundreds of millions to late-stage trials.

Digital Twins and Causal Models Replace Trial-and-Error

Noetik Inc. is building digital twins of individual patient tumors, trained on thousands of real cancer samples, to predict how each tumor will respond to specific therapies. The company recently secured a major non-exclusive partnership with GlaxoSmithKline to deploy the technology across GSK's oncology pipeline, signaling pharma's confidence that computational patient models can improve clinical decision-making.

Meanwhile, Insitro Inc. is generating what it calls "fit-for-purpose" data by modeling diseases like ALS in human cells at industrial scale, then using AI and genetics to create causal models that predict what happens when specific genes are turned up or down. This contrasts sharply with traditional approaches that rely on correlations from existing datasets.

According to RA Capital Management venture partner Jacob Oppenheim, AI's greatest near-term value isn't solving isolated discovery steps—it's expanding the hypothesis space and integrating human genetics data to identify which biological interventions will translate to clinical benefit.

From Computational Speed to Biological Data Infrastructure

The maturation of AI in biotech is evident in how companies are differentiating themselves. Sen-Jam Pharmaceutical claims its AI platform increases the probability of clinical success by 200-300% based on trial data from five immunomodulator assets now in Phase 2 for inflammaging-related diseases. Manifold Biotechnologies tests hundreds of thousands of AI-designed drug candidates simultaneously in single animals rather than sequentially, generating high-throughput in vivo data that improves tissue targeting, including blood-brain barrier penetration.

ExpressionEdits Ltd. uses AI to redesign the DNA instructions for therapeutic protein production, replacing 50-year-old viral genetic sequences with human-like code that achieves significantly higher protein expression—a critical manufacturing advantage that has attracted multiple large pharma partnerships.

Even more unconventional data sources are emerging. Fauna Bio mines the biology of hibernating mammals—which naturally repair heart damage, regrow muscle, and reverse neurodegeneration—combining this with human patient data through knowledge graphs and graph neural networks. The company is advancing a lead heart-failure therapy toward the clinic in 2027.

The Clinical Translation Challenge

Industry consensus is converging on a sobering reality: most drugs fail in clinical trials not because early discovery was flawed, but because researchers can't identify which patients will benefit. Concerto Biosciences, an MIT spinoff, has already completed Phase 1b trials for a once-weekly topical eczema therapy targeting multiple bacterial species, using proprietary high-throughput data and AI models to predict effective microbial combinations.

As the sector shifts from computational breakthroughs to building data infrastructure that translates AI predictions into approved therapies, companies like Alloy Therapeutics are positioning themselves as tech-enabled service providers spanning discovery through commercialization—functioning as collaborative "hyperscalers" for an industry learning that clinical success requires more than faster computers.

For patients with conditions like ALS, heart failure, and age-related inflammatory diseases, the promise is tangible: if these platforms deliver on their claimed improvements in clinical success rates, effective therapies could reach the market years faster than traditional development timelines allow.

Sources

1. Biotech companies are being reshaped by AI — SiliconANGLE